Global ADME
Toxicology Testing Market is Expected to Reach USD 14,319.9 Mn by 2022
The latest market report published by Credence Research,
Inc. “Global ADME Toxicology Testing Market - Growth, Share, Opportunities,
Competitive Analysis, and Forecast, 2016 - 2022,” the ADME toxicology testing
was valued at USD 6,986.2 Mn in 2015, and is expected to reach USD 14,319.9 Mn
by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.
Browse the full
report ADME Toxicology Testing Market - Growth, Share, Opportunities,
Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/adme-toxicology-testing-market
Market Insights
ADME is the abbreviation for absorption distribution,
metabolism and elimination, a pharmacology and pharmacokinetics term that
describes the disposition of a drug or compound inside the human body. ADME
comprises set of four processes that develop the performance of a drug on human
tissue and ADME toxicology testing is applied for the development of a new drug.
ADME toxicology facilitated pharmaceutical manufacturing company to minimize
their drug discovery time, testing complications, and to reduce the cost of
drug development. The growing application of ADME toxicology testing by
pharmaceuticals and biotechnology companies is assisting the market growth of
the ADME toxicology testing market.
One of the key factors responsible for late stage drug
failures is the inability of drug candidates to imitate in humans the safety
profile witnessed in animal models. Before
introduction and acceptance of ADME toxicology testing, drug development
process included toxicity and efficacy testing in in-vivo environment which was
responsible for late stage failure of drugs in human body due to anatomical and
genetic differences between animals and humans.
Download a sample
here @ http://www.credenceresearch.com/sample-request/57834
To overcome this barrier of drug failure manufacturers
across the globe opted for ADME toxicity testing in early drug developmental
phases of pre-clinical trials.
Increasing adoption of ADME toxicity testing as cost and time curbing
tool is further expected to drive growth of this market. Introduction of
technologically advanced computer based testing models are additionally
fuelling growth of this market. According to market stakeholders, recently
pre-clinical ADME toxicology testing is emerging to take on a new application
in the drug-discovery venture capital (VC) industry’s financial decision that
corresponds in importance and scope to its established role in the scientific
decisions of drug discovery firms.
Market Competition
Assessment
The ADME toxicology testing market is observed as the most
diversified and competitive market comprising large number of players. The market is dominated by several players,
depending on their major competencies. The key players in this market are
Cellartis AB, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo
Fisher Scientific, Inc., Caliper Life Sciences, Inc., Promega Corporation,
Cyprotex PLC, Beckman Coulter, Inc., Optivia Biotechnology, Inc., Accelrys,
Inc., Molecular Discovery Ltd., MultiCASE, Inc., Xceleron, Inc., ACEA
Biosciences, Inc., Albany Molecular Research, Inc., and CeeTox, Inc.
Key Market Movements
Rising application of ADME toxicology testing by
pharmaceuticals and biotechnology companies
Growing concerns over application of animals in clinical
trials
Increase in demand of cell-based assays in drug discovery
Escalating adoption of ADME toxicity testing as cost and
time curbing tool
No comments:
Post a Comment